T he paper by Bonnet et al. (1) in this issue of the Journal describes the results of a clinical trial of ivabradine, a drug that lowers heart rate by inhibiting the funny channel, a mechanism different from that of calcium-channel blockers or beta-blockers. This multisite, randomized, agestratified, double-blind, placebo-controlled trial studied 116 children with dilated cardiomyopathy and chronic heart failure and followed them for 12 months

中文翻译：

---

降低心率能否改善扩张型心肌病和慢性心力衰竭儿童的预后？＊

Bonnet 等人的论文。(1) 在本期杂志中，描述了伊伐布雷定的临床试验结果，这是一种通过抑制有趣通道来降低心率的药物，其机制与钙通道阻滞剂或 β 受体阻滞剂不同。这项多地点、随机、年龄分层、双盲、安慰剂对照试验研究了 116 名患有扩张型心肌病和慢性心力衰竭的儿童，并跟踪了他们 12 个月